Description FibroGen, Inc. is a biopharmaceutical company committed to discovering, developing, and commercializing a pipeline of first-in-class therapeutics. The Company applies its pioneering expertise in hypoxia-inducible factor (HIF) and connective tissue growth factor (CTGF) biology to advance innovative medicines for the treatment of unmet needs. The Company is currently developing and commercializing roxadustat, an oral small molecule inhibitor of HIF prolyl hydroxylase activity, for anemia associated with chronic kidney disease (CKD). Roxadustat is also in clinical development for chemotherapy-induced anemia (CIA). Pamrevlumab, an anti-CTGF human monoclonal antibody, is in clinical development for the treatment of locally advanced unresectable pancreatic cancer (LAPC) and metastatic pancreatic cancer. For more information, please visit www.fibrogen.com.
FibroGen has an employee rating of 3.9 out of 5 stars, based on 132 company reviews on Glassdoor which indicates that most employees have a good working experience there. The FibroGen employee rating is in line with the average (within 1 standard deviation) for employers within the Pharmaceutical & Biotechnology industry (3.5 stars).
To get a job at FibroGen, browse currently open positions and apply for a job near you. Once you get a positive response, make sure to find out about the interview process at FibroGen and prepare for tough questions.
Overall, 75% of employees would recommend working at FibroGen to a friend. This is based on 134 anonymously submitted reviews on Glassdoor.
68% of job seekers rate their interview experience at FibroGen as positive. Candidates give an average difficulty score of 3 out of 5 (where 5 is the highest level of difficulty) for their job interview at FibroGen.